- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued based on future growth
U.S. Pharmaceuticals & Biotech Undervalued based on future growth
Results
11
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
11 companies
Jazz Pharmaceuticals
Market Cap: US$6.7b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$108.50
7D
-2.4%
1Y
-3.9%
ACADIA Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$21.71
7D
-1.2%
1Y
45.6%
Alvotech
Market Cap: US$3.1b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$9.84
7D
-6.3%
1Y
-31.1%
Organon
Market Cap: US$2.6b
Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$10.04
7D
5.0%
1Y
-50.8%
Harmony Biosciences Holdings
Market Cap: US$2.0b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$33.33
7D
-4.9%
1Y
12.0%
Supernus Pharmaceuticals
Market Cap: US$1.9b
A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.
SUPN
US$32.77
7D
1.3%
1Y
23.4%
Phibro Animal Health
Market Cap: US$988.6m
Operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally.
PAHC
US$24.51
7D
2.6%
1Y
37.9%
SIGA Technologies
Market Cap: US$452.9m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.44
7D
9.5%
1Y
-14.7%
Protalix BioTherapeutics
Market Cap: US$122.6m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$1.49
7D
-5.7%
1Y
30.7%
Outlook Therapeutics
Market Cap: US$78.9m
Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
OTLK
US$1.83
7D
-3.9%
1Y
-76.2%
Minerva Neurosciences
Market Cap: US$12.5m
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
NERV
US$1.80
7D
-2.2%
1Y
-45.9%